Skip to main content

Search

Reset all filters
638 Result(s)
Sort by

BI_PharmAccess_launch_digital_healthcare_program

BI_PharmAccess_launch_digital_healthcare_program

Boehringer Ingelheim and PharmAccess launch a new mobile support program „Tiba Yako“ to empower patients to become more aware, access care and take charge of their disease management
Technologies

Technologies

We are expanding our global network of technology partners Learn more about partnering with us.
Practical Advice

Practical Advice

Practical advice for people with type 2 diabetes (T2D) at risk of heart disease
Avian influenza prevention at the source

Avian influenza prevention at the source

Teshome Mebatsion, Head of Viral Diseases Research at Boehringer Ingelheim, talks about the avian influenza virus, ways of prevention and scenarios for the future.
Avian influenza 5 things you should know

Avian influenza 5 things you should know

Communities across the globe are faced with outbreaks of bird flu. We stand with poultry farmers and veterinarians and supports the effort against the disease
Elke

Elke

People with Type 2 diabetes (T2D) have an increased risk of heart disease.
Professor Baumgart

Professor Baumgart

Information for people with type 2 diabetes (T2D) on why it is important to consider their heart and suggested measures that can be taken to reduce the risk of heart disease
Our Innovation Strategy

Our Innovation Strategy

A deep understanding of disease, identifying relevant mechanisms and choosing therapeutic modalities to address them is the core of our innovation strategy
CHMP_opinion_Nintedanib_SSc-ILD

CHMP_opinion_Nintedanib_SSc-ILD

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Biotherapeutics Discovery

Biotherapeutics Discovery

We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.